Preparation of Novel Supported Metallocene and their Olefin Polymerization Capabilities

Autor: Ds Hong, Si Woo Seong-Ihl Woo, Ts Seo Tae Seok Seo, Ys Ko

Publikováno v: Metalorganic Catalysts for Synthesis and Polymerization ISBN: 9783642642920

Cp2ZrCl2 confined inside the supercage of NaY zeolite (NaY/MAO/Cp2ZrCl2) provides shape-selective copolymerization in which comonomer reactivity ratio depends on the shape and size of comonomer. In ethylene/propylene copolymerization over NaY/MAO/Cp2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3295631b9e1250a9a94ae0862e61d3a2
https://doi.org/10.1007/978-3-642-60178-1_33

Best practice guidelines for use of reference points in radiation oncology information systems to aggregate longitudinal dosimetric data.

Autor: Witztum A; University of California, Department of Radiation Oncology, San Francisco, USA. Electronic address: alon.witztum@ucsf.edu., Jourani Y; Institut Jules Bordet, Medical Physics Department, Brussels, Belgium., Hirata EY; University of California, Department of Radiation Oncology, San Francisco, USA., McNutt T; Johns Hopkins University, Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, USA., Purdie TG; Princess Margaret Cancer Centre, Radiation Medicine Program, Toronto, Canada., Brock KK; The University of Texas MD Anderson Cancer Center, Department of Imaging Physics, Houston, USA., Hong DS; University of Southern California, Department of Radiation Oncology, Los Angeles, USA., Howard ME; University of Iowa, Department of Radiation Oncology, Iowa City, USA., Krauze AV; National Cancer Institute, NIH, Radiation Oncology Branch, Center for Cancer Research, Bethesda, USA., Balter PA; University of Southern California, Department of Radiation Oncology, Los Angeles, USA., Stockham AL; Mayo Clinic, Department of Radiation Oncology, Rochester, USA., Covington E; University of Michigan, Department of Radiation Oncology, Ann Arbor, USA., Xiao Y; University of Pennsylvania, Department of Radiation Oncology, Philadelphia, USA., Popple R; University of Alabama at Birmingham, Medical Physics Division, Birmingham, USA., Mayo CS; University of Michigan, Department of Radiation Oncology, Ann Arbor, USA.

Publikováno v: Practical radiation oncology [Pract Radiat Oncol] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.

A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.

Autor: Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tian Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alshawa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Onwugaje DOC; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albittar A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gurses S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sprenger A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Derbala MH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brink A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., How JA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moyers J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva IG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 247-254. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024).

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.

Autor: Dilly J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Hoffman MT; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Abbassi L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Li Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Paradiso F; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Parent BD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hennessey CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Jordan AC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Morgado M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Dasgupta S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Uribe GA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Yang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Kapner KS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hambitzer FP; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Qiang L; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Feng H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Geisberg J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Evans KE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lyu H; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Schalck A; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng N; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lopez AM; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bristow CA; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kim MP; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajapakshe KI; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bahrambeigi V; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roth JA; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Garg K; Exact Sciences, Redwood City, California., Guerrero PA; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Stanger BZ; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Cristea S; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard School of Public Health, Boston, Massachusetts., Lowe SW; Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York., Baslan T; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Mancias JD; Harvard Medical School, Boston, Massachusetts.; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Chan E; Amgen Inc., Thousand Oaks, California., Anderson A; Amgen Inc., Thousand Oaks, California., Katlinskaya YV; Amgen Inc., Thousand Oaks, California., Shalek AK; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.; Institute for Medical Engineering and Science, Department of Chemistry, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts., Hong DS; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Pant S; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Hallin J; Mirati Therapeutics Inc., San Diego, California., Anderes K; Mirati Therapeutics Inc., San Diego, California., Olson P; Mirati Therapeutics Inc., San Diego, California., Heffernan TP; Therapeutics Discovery Division, TRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chugh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Christensen JG; Mirati Therapeutics Inc., San Diego, California., Maitra A; Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Raghavan S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Nowak JA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Winter PS; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Dougan SK; Harvard Medical School, Boston, Massachusetts.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Publikováno v: Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2135-2161.

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions.

Autor: Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Thein KZ; Comprehensive Cancer Centers of Nevada-Central Valley, Las Vegas, NV 89169, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Publikováno v: Cancers [Cancers (Basel)] 2024 Oct 04; Vol. 16 (19). Date of Electronic Publication: 2024 Oct 04.